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The language-related transcription 
factor FOXP2 is post-translationally 
modified with small ubiquitin-like 
modifiers
Sara B. Estruch1, Sarah A. Graham1, Pelagia Deriziotis1 & Simon E. Fisher1,2
Mutations affecting the transcription factor FOXP2 cause a rare form of severe speech and language 
disorder. Although it is clear that sufficient FOXP2 expression is crucial for normal brain development, 
little is known about how this transcription factor is regulated. To investigate post-translational 
mechanisms for FOXP2 regulation, we searched for protein interaction partners of FOXP2, and 
identified members of the PIAS family as novel FOXP2 interactors. PIAS proteins mediate post-
translational modification of a range of target proteins with small ubiquitin-like modifiers (SUMOs). We 
found that FOXP2 can be modified with all three human SUMO proteins and that PIAS1 promotes this 
process. An aetiological FOXP2 mutation found in a family with speech and language disorder markedly 
reduced FOXP2 SUMOylation. We demonstrate that FOXP2 is SUMOylated at a single major site, which 
is conserved in all FOXP2 vertebrate orthologues and in the paralogues FOXP1 and FOXP4. Abolishing 
this site did not lead to detectable changes in FOXP2 subcellular localization, stability, dimerization or 
transcriptional repression in cellular assays, but the conservation of this site suggests a potential role 
for SUMOylation in regulating FOXP2 activity in vivo.
Heterozygous disruption of the FOXP2 gene, which encodes a member of the forkhead box (FOX) family of tran-
scription factors, leads to a rare and severe form of speech and language disorder (MIM 605317 (gene), 602081 
(disorder)). This developmental disorder was first described in a three-generation pedigree (the KE family), in 
which half of the family members have difficulties with learning to make co-ordinated orofacial movements 
underlying speech (childhood apraxia of speech), together with wide-ranging impairments in comprehension and 
production of spoken and written language, but without serious impact on other aspects of cognitive function-
ing1. All affected members of the KE family carry a missense mutation (R553H) within the FOX DNA-binding 
domain, which abolishes DNA binding and transcriptional repression by FOXP21–3. Around twenty further cases 
of speech/language disorder resulting from FOXP2 haploinsufficiency have since been reported, including non-
sense and frameshift point mutations, as well as chromosomal rearrangements disturbing the locus4–7. Thus, 
adequate FOXP2 expression appears to be essential for normal development of language-related brain circuits, 
presumably in order to establish correct expression levels of crucial downstream target genes involved in pro-
cesses such as neurite outgrowth and synaptic plasticity8,9.
FOXP2 shows evolutionarily-conserved expression in brain structures including the cortex, basal ganglia, 
thalamus and cerebellum10,11. Studies in animal models further support the notion that precisely controlled levels 
of FOXP2 are necessary for normal brain development (as reviewed in12,13). Mice in which both copies of the 
Foxp2 gene have been disrupted show severe motor impairments and developmental delay, and die 3–4 weeks 
after birth9,13 (Note that the murine orthologue of FOXP2 is designated as Foxp2 and orthologues in other species 
as FoxP2). When mice are heterozygous for a Foxp2 mutation equivalent to that found in the KE family, they are 
overtly normal, but exhibit deficits in motor skill learning and abnormal electrophysiology within cortico-striatal 
circuits9,13,14. Transient manipulation of Foxp2 levels also has deleterious consequences in the developing mouse 
brain: both knock-down and overexpression of Foxp2 have been reported to affect neurogenesis, neuronal 
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morphology and migration15,16. The effect of manipulating FoxP2 levels has also been investigated in the zebra 
finch, a species which, like humans, has the unusual ability to learn vocalizations from other individuals12. Both 
knock-down and overexpression of FoxP2 in key parts of the brains of juvenile zebra finches disrupt the normal 
process of song learning17,18, indicating that precise control of FoxP2 levels is necessary for normal vocal learning 
behaviour in this species.
Studies in songbirds indicate that, in addition to the spatial regulation of expression, dynamic temporal regu-
lation of activity of this transcription factor is important for its functions in the developing and adult brain. Zebra 
finch FoxP2 expression is elevated in a specific song-related brain region (Area X) during the critical period in 
which juvenile birds learn their song19,20. Furthermore, in adult birds, FoxP2 levels in Area X decrease when males 
practice songs alone, but not during performance of songs to females, which may contribute to the increased var-
iability in song output during solo practice compared to female-directed singing21–24. Similar dynamic regulation 
of the human orthologue could potentially play a role in vocal learning during speech acquisition.
While several studies have examined patterns of FOXP2 protein expression in the brains of different spe-
cies10,11,25, few investigations have addressed potential mechanisms for regulation of FOXP2 activity26. 
Transcription factor activity is often regulated via interaction with other transcription factors, co-repressors/
co-activators, chromatin-modifiers, and post-translational modification enzymes. Such interactions can alter 
protein turnover, increase or decrease transcriptional activation/repression activity, or influence selection of 
downstream targets. A small number of FOXP2-interacting proteins have been described, notably the paral-
ogues FOXP1 and FOXP4, the transcription factor TBR1, and the co-repressor CtBP127–30. To uncover addi-
tional mechanisms for regulation of FOXP2 activity we sought to identify novel protein interaction partners. We 
found that members of the PIAS family of proteins interact with FOXP2, and also with the paralogue FOXP1. 
PIAS proteins mediate post-translational modification of nuclear proteins with small ubiquitin-like modifiers 
(SUMOs)31,32. SUMOs are ubiquitously-expressed polypeptides that are reversibly coupled to many different pro-
teins with a variety of functional outcomes. We show that FOXP2 is modified with SUMOs at a single major 
evolutionarily-conserved site, and that PIAS1 promotes this modification. SUMOylation of FOXP2 is an excellent 
candidate mechanism for dynamic regulation of FOXP2 activity in vivo.
Results
FOXP2 interacts with members of the PIAS family of proteins. To identify candidate interaction 
partners of FOXP2, a screen of a human foetal brain yeast two-hybrid library was conducted using the full-length 
human protein as bait. The most frequently observed prey in this screen was PIAS1 (Supplementary Table S1). 
The vertebrate PIAS family includes four proteins with conserved domain architecture and 45–60% sequence 
identity (Fig. 1a). Interestingly, PIAS3 was one of four proteins identified as candidate FOXP2 interactors in an 
independent screen of a human foetal brain yeast two-hybrid library, also using full-length human FOXP2 as the 
bait33. PIAS proteins are known to interact with and modulate the activity of a range of transcription factors32,34. 
Members of the PIAS family therefore appeared to be strong candidates for FOXP2 interaction partners.
In order to confirm the interaction of FOXP2 with PIAS proteins, we used a Bioluminescence Resonance 
Energy Transfer (BRET) assay, which allows protein-protein interactions to be monitored in live mammalian cells 
in culture29. In the BRET assay, a protein of interest is expressed as a fusion with Renilla luciferase (Luc) and a can-
didate interaction partner is expressed as a fusion with yellow fluorescent protein (YFP). An interaction between 
the two proteins brings the Luc and YFP moieties into sufficient proximity to allow resonance energy transfer to 
occur upon addition of a luciferase substrate, shifting the wavelength of the emitted light from 480 nm to 530 nm. 
Using Luc-FOXP2 and YFP-PIAS fusion proteins, we confirmed that FOXP2 interacts with PIAS1 and PIAS3, and 
in addition demonstrated interaction with PIAS4, and a potential weaker interaction with PIAS2 (Fig. 1b). Note 
that all experiments were performed using HEK293 cells, unless indicated otherwise.
We noted that PIAS proteins exhibited nuclear localization with a distinctive speckled appearance, as has been 
reported previously34. We therefore examined if co-expression of PIASs with FOXP2 would cause redistribution 
of FOXP2, which normally exhibits a diffuse localization within nuclei. Expression of PIAS1 together with FOXP2 
caused a dramatic change, involving extensive co-localization of FOXP2 with PIAS1 in nuclear speckles (Fig. 1c). 
A similar effect was observed upon expression of PIAS3 and PIAS4, consistent with the interaction observed 
in the BRET assay. Upon overexpression of PIAS2, FOXP2 retained a largely diffuse nuclear distribution, with 
little FOXP2 exhibiting co-localization with PIAS2 within speckles, consistent with the lower level of interaction 
observed between FOXP2 and PIAS2 in BRET experiments. The interaction between FOXP2 and PIASs may 
therefore draw FOXP2 into nuclear speckles.
To try to identify the region of FOXP2 involved in binding to PIAS proteins, we performed BRET assays 
using a series of synthetic, truncated versions of FOXP228 (Fig. 1d). These truncations appear to be effective in 
mapping interaction sites because deletion of the region containing residues 330–487, which contains the leucine 
zipper dimerization domain30, results in a substantial reduction in interaction with full-length FOXP2 (Fig. 1d, 
centre). Notably, even the shortest FOXP2 truncation tested (residues 1–258) retained the ability to interact with 
PIAS1, though perhaps to a slightly lesser degree than the full-length protein (Fig. 1d, right). These results sug-
gest that some key determinants of PIAS binding reside within the N-terminal region of FOXP2. Apart from a 
polyglutamine tract, this region does not contain any known domains, but it does include regions of polypeptide 
that are highly conserved in FOXP1 and FOXP4, and has also been identified as the region interacting with the 
autism-related transcription factor TBR1, suggesting that this region may coordinate multiple protein-protein 
interactions28.
FOXP2 is SUMOylated. PIAS proteins function as SUMO E3 ligases, promoting the transfer of SUMO from 
the SUMO-conjugating enzyme UBC9 to an acceptor lysine residue in a target protein, in a manner analogous 
to the transfer of ubiquitin to proteins by ubiquitin E3 ligases31,32. There are three SUMO proteins in vertebrates, 
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Figure 1. FOXP2 interacts with members of the PIAS family of SUMO E3 ligases. (a) Top: schematic 
representation of human PIAS proteins. Domains are shaded in dark blue: SAP domain (SAP); PINIT domain 
(PINIT); SP-RING domain (SP-RING); acidic domain (AD); serine/threonine-rich domain (S/T). The number 
of amino acid residues is shown to the right of the schematic. Bottom: identity matrix for PIAS proteins.  
(b) BRET assay for interaction between FOXP2 and PIAS proteins. HEK293 cells were transfected with 
luciferase-FOXP2 (donor) and YFP-PIAS (acceptor). The control donor protein is a nuclear-targeted luciferase. 
Values are mean corrected BRET ratios ± S.E.M. (n = 3). (c) Fluorescence micrographs of HEK293 cells 
transfected with mCherry-PIAS (red) and YFP-FOXP2 (green). Nuclei were stained with Hoechst 33342 (blue). 
(d) Left panel: Schematic representation of synthetic truncated forms of FOXP2. The number of amino acid 
residues is shown on the left; 1–715 represents the full-length protein. Known domains are shown in dark blue: 
glutamine-rich region (Q-rich); zinc finger (ZF); leucine zipper (LZ); forkhead domain (FOX). A nuclear-
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SUMO1, SUMO2 and SUMO3, all of which have a molecular weight of 11 kDa. SUMO2 and SUMO3 have 
~95% amino acid sequence identity and are thought to be functionally very similar, whereas SUMO1 has only 
~50% amino acid sequence identity with SUMO2/3 and is not functionally redundant with these proteins31. The 
SUMOylation of specific proteins is typically difficult to detect due to the dynamic nature of the modification, 
which is readily removed by SUMO-specific proteases of the SENP family, and the fact that only a minor pro-
portion of target protein molecules carry a SUMO moiety at any one time31. To facilitate detection of protein 
SUMOylation, the 18 kDa SUMO-conjugating enzyme UBC9 can be fused to a target protein of interest35. We 
therefore generated a FOXP2-UBC9 fusion construct, which also carries a V5 epitope tag to enable the fusion to 
be detected independently from endogenous FOXP2 (Fig. 2a).
We transfected cells with FOXP2-UBC9 together with a YFP-fusion of SUMO1, SUMO2 or SUMO3. The 
use of YFP-tagged SUMOs allows discrimination between proteins modified with endogenous and exogenous 
SUMO. Lysates of transfected cells were probed by western blotting with anti-V5 antibody to detect any shift in 
the migration of FOXP2-UBC9 resulting from SUMOylation (Fig. 2b). All samples contained a FOXP2-UBC9 
species that migrated at ~110 kDa, representing unSUMOylated protein. Cells transfected with FOXP2-UBC9 
and a YFP-SUMO contained a ~170 kDa FOXP2-UBC9 species that was not present in control cells transfected 
with FOXP2-UBC9 and YFP, indicating that FOXP2 can be SUMOylated with all three SUMOs (Fig. 2b). To 
confirm that the ~170 kDa species represents YFP-SUMO conjugated to FOXP2-UBC9, we generated mutant 
forms of YFP-SUMO, in which the two C-terminal glycine residues required for conjugation to target proteins 
(and to UBC9) were mutated to alanine. As expected, cells transfected with FOXP2-UBC9 together with an ala-
nine mutant YFP-SUMO did not contain the ~170 kDa species (Fig. 2b). In cells transfected with FOXP2-UBC9 
together with a mutant YFP-SUMO or YFP alone, a ~130 kDa FOXP2-UBC9 species was observed, which may 
represent FOXP2-UBC9 modified with endogenous SUMO (Fig. 2b). Note that the observed molecular weights 
of the different FOXP2-UBC9 species do not necessarily correspond with theoretical values because SUMOylated 
proteins are branched polypeptides and exhibit anomalous migration.
In order to confirm the results of the gel shift assay, we also examined FOXP2 SUMOylation in a BRET assay 
using Luc-FOXP2 with YFP-SUMO fusion proteins. Interaction of FOXP2 was observed with SUMO1, SUMO2 
and SUMO3, but not with their respective alanine mutants, in agreement with the gel shift assay (Fig. 2c). Notably, 
the BRET assay readily allows detection of FOXP2 SUMOylation without the need to fuse FOXP2 to UBC9, indi-
cating that the technique is highly sensitive for monitoring SUMOylation. BRET has rarely been used in studies 
of SUMOylation, but may be a widely applicable technique for examining this modification, with the advantage 
that its use in live cells overcomes the difficulties in maintaining protein SUMOylation encountered in most 
experimental procedures.
PIAS1 promotes SUMOylation of FOXP2. To determine if PIAS proteins are involved in the 
SUMOylation of FOXP2, we focused on PIAS1, the PIAS family member identified in the original yeast 
two-hybrid screen. We tested if overexpression of PIAS1, together with SUMO, would allow SUMOylation of 
FOXP2 to be detected in a gel shift assay without the need to fuse FOXP2 to UBC9. Overexpression of myc-tagged 
PIAS1 together with any of the three SUMO proteins (fused to mCherry) gave rise to a new FOXP2 species of 
~140 kDa, suggesting that PIAS1 is able to stimulate SUMOylation of FOXP2 (Fig. 3a). Importantly, the observa-
tion of a new high molecular weight FOXP2 species in this experiment shows that FOXP2 can be SUMOylated 
without being fused to UBC9.
To confirm that the increase in SUMOylation was mediated directly by PIAS1, we generated a catalytically 
inactive version of PIAS1 that has a point mutation (C350S) within the SP-RING domain, which is involved in 
the recognition of target proteins (Fig. 3b)32,36. The C350S PIAS1 mutant was unable to interact with FOXP2 in a 
BRET assay, indicating that the SP-RING domain may be involved in recognition of FOXP2 as a SUMOylation 
target (Fig. 3b). The C350S mutant displayed a more diffuse nuclear localization than wild-type PIAS1, suggesting 
that the localization of PIAS1 within nuclear speckles is connected to its activity as a SUMO E3 ligase (Fig. 3c). 
Consistent with this, the C350S mutant did not induce redistribution of FOXP2 into nuclear speckles (Fig. 3c). 
In a gel shift assay, wild-type PIAS1 promoted the modification of FOXP2-UBC9 with both endogenous SUMO 
(~130 kDa species) and mCherry-tagged SUMO (~170 kDa species) (Fig. 3d). The C350S mutant was unable to 
promote SUMOylation of FOXP2-UBC9 (Fig. 3d), indicating that the increase in FOXP2 SUMOylation observed 
upon PIAS1 overexpression is due to the SUMO E3 ligase activity of PIAS1.
K674 is the major SUMOylation site in FOXP2. SUMOs are conjugated to target proteins via an isopep-
tide bond formed by the C-terminal carboxyl group of SUMO and the amino group of a lysine side chain in the 
target protein. Lysine residues that are subject to SUMOylation are often found within the consensus sequence 
Ψ KX(D/E), where Ψ is a hydrophobic amino acid and X is any amino acid, although many SUMOylation sites 
do not conform to this pattern37. We used three prediction algorithms to identify potential SUMOylation sites 
in FOXP2: SUMOplot (www.abgent.com/sumoplot), GPS-SUMO (sumosp.biocuckoo.org)38, and JASSA (www.
targeting signal (shown in black) was appended to the C-terminus of variants 1–487, 1–329, and 1–258 because 
these variants lack endogenous nuclear targeting signals. Centre panel: BRET assay for interaction between 
synthetic FOXP2 truncations and wild-type FOXP2. HEK293 cells were transfected with luciferase-FOXP2 
truncations (donor) and YFP-FOXP2 (acceptor) Right panel: BRET assay for the interaction between synthetic 
FOXP2 truncations and PIAS1. HEK293 cells were transfected with luciferase-FOXP2 truncations (donor) and 
YFP-PIAS1 (acceptor). The control donor protein is a nuclear-targeted luciferase. Values are mean corrected 
BRET ratios ± S.E.M. (n = 3).
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jassa.fr)39. All three algorithms identified K674 as a high-confidence potential SUMOylation site (Supplementary 
Table S2). No other lysine residues in FOXP2 were identified as potential SUMOylation sites by more than one 
algorithm. Residue K674 lies in the C-terminal region of FOXP2, which does not contain any previously described 
functional domains, consistent with the typical localization of SUMOylation sites within structurally disordered 
regions of polypeptide (Fig. 4a)40. This residue is within a VKEE sequence that matches the consensus Ψ KX(D/E) 
motif (Fig. 4b). In addition, the putative SUMOylation site at K674 belongs to a class of predicted SUMOylation 
sites termed KEPE motifs, which have the consensus sequence Ψ KX(D/E)PXXX(D/E)41. KEPE motifs are found 
in over 130 human proteins, and are enriched among proteins involved in transcription41. The critical residues of 
the KEPE motif are conserved in vertebrate FOXP2 proteins, supporting a functional role for the motif (Fig. 4b).
To assess if K674 functions as a SUMOylation site, we mutated this residue to arginine, thus removing the 
amino group required for SUMO conjugation but preserving the positive charge at this position of the polypep-
tide. We performed a gel shift assay using wild-type or mutant FOXP2-UBC9 co-transfected with PIAS1 and each 
Figure 2. FOXP2 can be SUMOylated with SUMO1, 2 and 3. (a) Schematic representation of the FOXP2-
UBC9 fusion protein with an N-terminal V5 epitope tag. (b) Gel shift assay for FOXP2 SUMOylation. FOXP2-
UBC9 was expressed in HEK293 cells together with a YFP-fusion of either wild-type SUMO (GG), or mutant 
SUMO in which the two C-terminal glycine residues required for conjugation to the target protein were 
mutated to alanine (AA), or with YFP alone (control). Top panel: western blot probed with anti-V5 antibody to 
detect FOXP2-UBC9. The 110 kDa species is unmodified FOXP2-UBC9. The 130 kDa species is FOXP2-UBC9 
modified with endogenous SUMO. The 170 kDa species is FOXP2-UBC9 modified with YFP-SUMO. Middle 
panel: western blot probed with anti-YFP antibody. The asterisk indicates unconjugated YFP-SUMO. Higher 
molecular weight species are cellular proteins modified with YFP-SUMO. Bottom panel: western blot probed 
with anti-β -actin to confirm equal loading. (c) BRET assay for interaction between FOXP2 and SUMO. HEK293 
cells were transfected with luciferase-FOXP2 (donor) and YFP-SUMO (acceptor), using either wild-type SUMO 
(GG) or alanine mutants (AA). The control donor protein is a nuclear-targeted luciferase. Values are mean 
corrected BRET ratios ± S.E.M. (n = 3).
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of the three SUMOs. In this assay, the ~170 kDa SUMOylated FOXP2-UBC9 species observed in cells transfected 
with wild-type FOXP2 was not present in cells transfected with the K674R mutant (Fig. 4c). Thus K674 is the 
major site in FOXP2 that is subject to modification by SUMO1, SUMO2 and SUMO3.
Figure 3. PIAS1 promotes FOXP2 SUMOylation. (a) Gel shift assay for SUMOylation of FOXP2. HEK293 
cells were transfected with V5-tagged FOXP2 and mCherry-SUMO, together with myc-tagged PIAS1 (+) or 
an empty vector (−). Top panel: western blot probed with anti-V5 antibody. The 90 kDa species is unmodified 
FOXP2. The 140 kDa species is FOXP2 modified with mCherry-SUMO. Second panel: western blot probed 
with anti-mCherry. The asterisk indicates unconjugated mCherry-SUMO. Higher molecular weight species 
are cellular proteins modified with mCherry-SUMO. Third panel: western blot probed with anti-myc tag 
to detect PIAS1. Bottom panel: western blot probed with anti-β -actin to confirm equal loading. (b) Top: 
schematic representation of PIAS1 C350S mutant. Bottom: BRET assay for interaction of FOXP2 with PIAS1. 
HEK293 cells were transfected with luciferase-FOXP2 (donor) and YFP-PIAS1 (wild-type (WT) or C350S 
mutant, acceptor). The control donor protein is a nuclear-targeted luciferase. Values are mean corrected BRET 
ratios ± S.E.M. (n = 3). (c) Fluorescence micrographs of HEK293 cells transfected with mCherry-tagged wild-
type PIAS1 (WT) or C350S mutant (red) and YFP-FOXP2 (green). Nuclei were stained with Hoechst 33342 
(blue). (d) Gel shift assay for SUMOylation of FOXP2. HEK293 cells were transfected with FOXP2-UBC9 
together with mCherry-SUMO or mCherry alone (control) and myc-tagged wild-type PIAS1 (+), C350S 
mutant (M) or empty vector (−). Top panel: western blot probed with anti-V5 antibody to detect FOXP2-
UBC9. The 110 kDa species is unmodified FOXP2-UBC9. The 130 kDa species is FOXP2-UBC9 modified with 
endogenous SUMO. The 170 kDa species is FOXP2-UBC9 modified with mCherry-SUMO. Second panel: 
western blot probed with anti-mCherry antibody. The asterisk indicates unconjugated mCherry-SUMO. Higher 
molecular weight species are cellular proteins modified with mCherry-SUMO. Third panel: western blot probed 
with anti-myc to detect PIAS1. Fourth panel: western blot probed with anti-β -actin to confirm equal loading. 
Bottom panel: densitometry analysis of FOXP2-UBC9 species.
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Figure 4. K674 is the major SUMOylation site in FOXP2. (a) Schematic representation of FOXP2 showing 
the predicted SUMOylation site. Known domains are shown in dark blue: glutamine-rich region (Q-rich); zinc 
finger (ZF); leucine zipper (LZ); forkhead domain (FOX). (b) Sequence alignment of the region surrounding 
the putative SUMOylation site in FOXP2 orthologues. Conserved residues are shown on a black background. 
Critical residues of the KEPE-type SUMOylation site motif are shown in turquoise. UniProt accession numbers: 
Homo sapiens O15409; Pan troglodytes Q8MJ98; Mus musculus P58463; Gallus gallus Q5IHK1; Xenopus laevis 
www.nature.com/scientificreports/
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The dramatic reduction in SUMOylation resulting from mutation of residue K674 suggests that this residue 
may be the most important SUMOylation site in vivo. To detect if a proportion of FOXP2 might be SUMOylated 
at alternative sites, we employed a HeLa cell line stably expressing His-tagged SUMO342. Using cobalt affinity 
purification under denaturing conditions, SUMOylated species were purified from HeLa-SUMO3 cells trans-
fected with YFP-tagged wild-type FOXP2, YFP-tagged K674R mutant, or YFP alone (Fig. 4d). YFP-FOXP2 
was detected in the affinity-purified protein fraction from the HeLa-SUMO3 cells, confirming that FOXP2 can 
be SUMOylated without being fused to UBC9 (Fig. 4d). Note that in this key experiment we did not detect 
an observable shift in the molecular weight of FOXP2 as a result of SUMOylation, in contrast to the clear size 
shifts observed in our earlier experiments. One potential explanation of the discrepancy is that this experiment 
employed His-tagged SUMO, with a molecular weight of only ~10 kDa, comparable to that of endogenous SUMO, 
while our prior experiments used YFP- and mCherry-tagged SUMO proteins, which have substantially higher 
molecular weights of >35 kDa. Importantly, YFP-FOXP2 was not detectable among proteins eluted from resin 
incubated with lysate from the parental HeLa cell line, demonstrating that FOXP2 does not bind non-specifically 
to the affinity resin (Fig. 4d). Moreover, the YFP control protein was not detectable in the affinity-purified fraction 
from the HeLa-SUMO3 cells, demonstrating that only SUMOylated proteins are purified using this procedure 
(Fig. 4d).
The K674R mutant was also present in the affinity-purified material from the HeLa-SUMO3 cell line, indi-
cating that specific enrichment of SUMOylated proteins allows detection of rarer forms of FOXP2 that are 
SUMOylated at one or more alternative sites (Fig. 4d). Different SUMOylation site prediction tools variously 
identify potential additional SUMOylation sites at K74, K285, K417 and K560 (Supplementary Table S2). 
However, none of these predictions are consistent across two or more prediction tools, and none lie within a typi-
cal consensus SUMOylation motif. While it is possible that several additional sites in FOXP2 may occasionally be 
SUMOylated, modification at these sites may not serve a critical biological function.
In a BRET assay, the K674R mutant displayed consistently reduced, but not abolished, interaction with 
wild-type SUMO1, SUMO2 and SUMO3, and no interaction with the respective alanine mutants (Fig. 4e). The 
residual interaction between the K674R mutant and SUMOs in the BRET assay might be accounted for by the 
presence of minor secondary SUMOylation sites. Given that the reduction in the BRET signal resulting from the 
K674R mutation is modest, there may also be a contribution to this signal from non-covalent association of the 
mutant with SUMO. Low-affinity, non-covalent interactions between SUMOs and other proteins are mediated by 
SUMO-interaction motifs (SIMs)31. We employed the JASSA39 and GPS-SUMO38 algorithms to identify potential 
SIMs in FOXP2, but no high-confidence SIMs were found (Supplementary Table S3).
SUMO may instead associate with the K674R mutant as part of a complex with UBC9 and PIAS. In support of 
this model, the K674R mutant exhibited a similar degree of interaction with PIASs as wild-type FOXP2 in a BRET 
assay (Fig. 4f). We also observed co-localization of the K674R mutant with PIASs in nuclear speckles (Fig. 4g). 
Therefore K674 is not required for interaction of FOXP2 with PIAS proteins, consistent with the mapping of the 
PIAS binding site to the N-terminal region of FOXP2 (Fig. 1d). Furthermore, the relocalization of FOXP2 to 
nuclear speckles that is observed upon overexpression of PIASs appears to be due to the interaction between PIAS 
and FOXP2, and not to the SUMOylation of FOXP2.
Functional consequences of FOXP2 SUMOylation. SUMOylation can affect the function of transcrip-
tion factors in several ways31. To identify potential effects of SUMOylation on FOXP2 function, we assessed if the 
K674R SUMOylation site mutant displayed any altered properties in cellular assays. The mutant did not exhibit 
any differences in subcellular localization, retaining a diffuse nuclear distribution (Fig. 5a). To assess differences 
in protein expression level, we transfected cells with YFP fusions of wild-type FOXP2 or the K674R mutant, and 
measured fluorescence intensity over time, relative to the fluorescence intensity of co-transfected mCherry. No 
differences were observed in the ultimate expression level of the wild-type and mutant proteins, or in the time 
course of induction of expression (Fig. 5b). To test for differences in protein degradation, cycloheximide was 
added to cells expressing wild-type FOXP2 or the K674R mutant to arrest protein synthesis, and the decrease 
Q4VYS1; Danio rerio Q4JNX5. (c) Gel shift assay for FOXP2 SUMOylation. HEK293 cells were transfected 
with FOXP2-UBC9 (wild-type (WT) or K674R mutant) together with YFP-SUMOs or YFP alone (control). Top 
panel: western blot probed with anti-V5. The 110 kDa species is unmodified FOXP2-UBC9. The 130 kDa species 
is FOXP2-UBC9 modified with endogenous SUMO. The 170 kDa species is FOXP2-UBC9 modified with YFP-
SUMO. Bottom panel: western blot probed with anti-β -actin. (d) Pull-down assay for FOXP2 SUMOylation. 
HeLa cells stably expressing His-tagged SUMO3, or the parental HeLa cell line (control), were transfected 
with YFP-FOXP2 (wild-type (WT) or K674R mutant) or YFP alone. His-tagged species were isolated under 
denaturing conditions using cobalt affinity purification. Western blots of total lysate (input) and affinity-purified 
material (elution) were probed with anti-His tag antibody to visualize SUMO-conjugated proteins (top panel). 
YFP and YFP-FOXP2 were visualized using anti-GFP antibody: FOXP2 is indicated by an arrowhead and YFP 
with an asterisk (middle panel). Total protein was visualized by Coomassie blue staining (bottom panel).  
(e) BRET assay for interaction of FOXP2 with SUMO. HEK293 cells were transfected with luciferase-FOXP2 
(wild-type (WT) or K674R mutant, donor) and YFP-SUMO (wild-type (GG) or alanine mutant (AA), 
acceptor). The control is a nuclear-targeted luciferase. Values are mean corrected BRET ratios ± S.E.M. (n = 3). 
(f) BRET assay for interaction of FOXP2 and PIAS proteins. Cells were transfected with luciferase-FOXP2 
(wild-type (WT) or K674R mutant, donor) and YFP-PIAS (acceptor). (g) Fluorescence micrographs of HEK293 
cells transfected with mCherry-PIAS (red) and YFP-FOXP2 K674R mutant (green). Nuclei were stained with 
Hoechst 33342 (blue).
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in FOXP2 protein over time was monitored by western blotting. For both wild-type and mutant FOXP2, the 
amount of protein had dropped to approximately 25% of starting levels after 6 h incubation with cycloheximide, 
and no difference in the rate of degradation was observed between the wild-type and mutant proteins (Fig. 5c). 
Abolishing the major SUMOylation site therefore does not have a substantial effect on FOXP2 turnover in cul-
tured cells. It is possible that differences in stability might be evident after longer incubations with cycloheximide, 
but reliable quantification of FOXP2 is precluded by the low levels of remaining protein.
To determine if SUMOylation might affect the transcriptional regulatory activity of FOXP2, we employed 
a luciferase reporter assay in which luciferase expression is driven by the SV40 viral promoter3. As previously 
Figure 5. Abolishing the K674 SUMOylation site has no effect in cellular assays of FOXP2 function. (a) 
Fluorescence micrographs of cells transfected with YFP-tagged wild-type (WT) and K674R mutant forms 
of FOXP2. Nuclei were stained with Hoechst 33342 (blue). (b) Fluorescence-based measurement of FOXP2 
expression level. HEK293 cells were transfected with YFP-FOXP2 (wild-type (WT) or K674R mutant), together 
with mCherry for normalization. Fluorescence intensity was measured 24, 36 and 48 h post-transfection. Values 
are mean YFP/mCherry fluorescence ratios ± S.E.M. (n = 3), relative to the value for wild-type FOXP2 at 48 h. 
(c) Western blot assay for FOXP2 degradation. HEK293 cells were transfected with V5-tagged FOXP2 (wild-
type (WT) or K674R mutant). Cycloheximide (CHX) was added to cells 48 h after transfection for varying 
amounts of time. Top: western blots of whole cell extracts probed with anti-V5 and anti-β -actin antibodies. 
Bottom: densitometry quantification of FOXP2. Values are normalized to β -actin and plotted relative to the 0 h 
time point. (d) Luciferase reporter assays for transcriptional regulatory activity of FOXP2. HEK293 cells were 
transfected with a luciferase reporter vector containing the SV40 promoter (left) or the human SRPX2 promoter 
(right), together with YFP-FOXP2 (wild-type (WT), K674R or R553H mutants), or YFP alone (control). 
Values are mean relative luciferase activity ± S.E.M. (n = 3), expressed relative to the control. Asterisks indicate 
significant differences compared to wild-type FOXP2 (p < 0.05, one-tailed student’s t-test). NS, not significant. 
Exact p-values for the SV40 assay are 0.0043 for the control, 0.0048 for R553H, 0.1598 for K674R. Exact 
p-values for the SRPX2 assay are 0.0009 for the control, 0.0017 for R553H, and 0.2566 for K674R. (e) BRET 
assay for FOXP2 dimerization. HEK293 cells were transfected with luciferase-FOXP2 (wild-type (WT) or 
K674R mutant, donor) and YFP-FOXP2 (acceptor). The control is a nuclear-targeted luciferase. Values are mean 
corrected BRET ratios ± S.E.M. (n = 3). (f) BRET assay for interaction of FOXP2 with CtBP1. HEK293 cells 
were transfected with luciferase-FOXP2 (wild-type (WT) or K674R mutant, donor) and YFP-CtBP1 (acceptor). 
The control is a nuclear-targeted luciferase. Values are mean corrected BRET ratios ± S.E.M. (n = 3).
www.nature.com/scientificreports/
1 0Scientific RepoRts | 6:20911 | DOI: 10.1038/srep20911
Figure 6. The R553H FOXP2 mutant which causes speech/language disorder exhibits reduced 
SUMOylation. (a) Schematic representation of the FOXP2 R553H mutant. Known domains are shown in  
dark blue: glutamine-rich region (Q-rich); zinc finger (ZF); leucine zipper (LZ); forkhead domain (FOX).  
(b) Gel shift assay for FOXP2 SUMOylation. HEK293 cells were transfected with V5-tagged FOXP2 (wild-type 
(WT), K674R or R553H mutant) together with mCherry-SUMO and myc-tagged PIAS1. Top panel: western 
blot probed with anti-V5 antibody. The 90 kDa species is unmodified FOXP2. The 140 kDa species is FOXP2 
modified with mCherry-SUMO. Second panel: western blot probed with anti-myc tag antibody to detect 
PIAS1. Third panel: western blot probed with anti-mCherry. The asterisk indicates unconjugated mCherry-
SUMO. Higher molecular weight species are cellular proteins modified with mCherry-SUMO. Bottom panel: 
western blot probed with anti-β -actin to confirm equal loading. (c) BRET assay for interaction of FOXP2 with 
SUMO. HEK293 cells were transfected with luciferase-FOXP2 (wild-type (WT) or R553H mutant, donor) 
and YFP-SUMO (wild-type (GG) or alanine mutant (AA), acceptor). The control donor protein is a nuclear-
targeted luciferase. Values are mean corrected BRET ratios ± S.E.M. (n = 3). (d) BRET assay for interaction of 
FOXP2 with PIAS proteins. HEK293 cells were transfected with luciferase-FOXP2 (wild-type (WT) or R553H 
mutant, donor) and YFP-PIAS (acceptor). The control donor protein is a nuclear-targeted luciferase. Values 
are mean corrected BRET ratios ± S.E.M. (n = 3). (e) Fluorescence micrographs of HEK293 cells transfected 
with mCherry-PIAS (red) and YFP-FOXP2 R553H mutant (green). Nuclei were stained with Hoechst 33342 
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reported, wild-type FOXP2 repressed luciferase activity by around 60%, whereas the mutant FOXP2 found in the 
KE family (R553H), which is unable to bind DNA, did not repress luciferase activity (Fig. 5d)3. The K674R mutant 
did not differ significantly in its repressive capability from the wild-type protein (Fig. 5d). A luciferase assay was 
also performed using the human SRPX2 promoter. It has previously been reported that FOXP2 represses tran-
scription from this promoter43. In our assay, wild-type FOXP2 substantially repressed luciferase activity, and the 
R553H mutant showed loss of repression, but the K674R mutant again did not differ significantly in its repressive 
capability from the wild-type protein (Fig. 5d). Thus the loss of the SUMOylation site does not have a generalized 
effect on the repressive capability of FOXP2.
We then looked to see if abolishing the SUMOylation site affects the ability of FOXP2 to form homodimers30. 
The mutant displayed normal dimerization ability in a BRET assay (Fig. 5e), as might be expected given that 
FOXP2 dimerization is mediated by the leucine zipper domain, which is not located near to the SUMOylation site 
(Fig. 4a)29,30. Finally we employed a BRET assay to assess if the K674R mutant differed in its ability to bind to the 
co-repressor CtBP129,30. Again, no differences were observed between the wild-type and mutant proteins (Fig. 5f). 
Thus, in our cell-based assays, abolishing the major SUMOylation site in FOXP2 does not have a substantial 
impact on the behaviour of the protein.
A FOXP2 mutant that causes speech/language disorder shows reduced SUMOylation. Members 
of the KE family who are affected by speech and language disorder all carry a heterozygous mutation, R553H, 
within the DNA-binding domain of FOXP2 (Fig. 6a)1. This mutation affects a critical residue within the 
DNA-recognition helix of the FOX domain and abolishes DNA binding1–3,44. Unexpectedly, a gel shift assay in 
which cells were transfected with wild-type or mutant FOXP2, together with PIAS1 and SUMO, showed a clear 
reduction in SUMOylation of the R553H mutant, though it was still modified to a greater extent than the K674R 
mutant (Fig. 6b). A BRET assay also showed a near total loss of interaction between SUMOs and the R553H 
mutant in comparison to wild-type FOXP2 (Fig. 6c), in contrast to the partially retained interaction between 
SUMOs and the K674R mutant (Fig. 4d).
Given that the major SUMOylation site is intact in the R553H mutant, the reduction in SUMOylation may 
be a consequence of reduced interaction between the mutant and components of the SUMOylation machin-
ery, such as PIASs or UBC9. Consistent with this possibility, the R553H mutant showed reduced or abolished 
interaction with PIASs in a BRET assay (Fig. 6d). The R553H mutant continued to show some co-localization 
with PIASs in transfected cells, however the tendency of this mutant to form aggregates makes it unclear if the 
punctae containing both proteins are nuclear speckles or protein aggregates (Fig. 6e)3. Decreased interaction 
with PIAS1 could account for the relatively higher level of R553H SUMOylation in the gel shift assay compared 
to the BRET assay, because the overexpression of PIAS1 in the gel shift assay might have a compensatory effect on 
SUMOylation. Interestingly, the R553H mutant was SUMOylated to a similar extent as wild-type FOXP2 when 
these proteins were fused to UBC9 (Fig. 6f), suggesting that fusion to UBC9 might rescue a loss of interaction 
with the SUMOylation machinery in the R553H mutant.
Thus in contrast to the K674R mutant, which is able to interact with PIASs but cannot be SUMOylated, the 
R553H mutant has reduced interaction with PIASs, but can still be SUMOylated by employing overexpression of 
PIAS or fusion to UBC9. It is unexpected that the R553H mutation should reduce interaction with PIASs, because 
truncated forms of FOXP2 that lack the entire FOX domain, and are thus also unable to bind DNA, are still able 
to interact with PIAS1 (Fig. 1d). The partial mislocalization and increased propensity for protein aggregation 
resulting from the R553H mutation may contribute to the reduction in interaction, although the majority of 
mutant protein still displays a normal diffuse nuclear localization, and retains the ability to interact with wild-type 
FOXP2, indicating that the mutation does not cause gross misfolding of the entire population of molecules3,29. 
Potentially the R553H mutation causes a conformational change that blocks the PIAS binding site. Alternatively, 
the loss of DNA-binding capacity and/or destabilization of the FOX domain resulting from the R553H mutation 
may permit interactions with other cellular proteins, such as those involved in protein degradation, that in turn 
interfere with PIAS binding. Although the mechanism by which the R553H mutation reduces interaction with 
PIAS is unclear, it seems likely that a functional FOX domain is needed in addition to the K674 SUMOylation site 
to permit normal levels of FOXP2 SUMOylation in cells.
SUMOylation of other FOXP proteins. FOXP2 has three mammalian paralogues, FOXP1, FOXP3 
and FOXP4 (Fig. 7a). FOXP1, FOXP2 and FOXP4 exhibit 55–65% sequence identity, are able to form heterod-
imers, and are expressed in overlapping cell populations in the brain and other organs, suggesting that they 
may co-operate in the regulation of certain subsets of target genes10,30,45. FOXP3 is structurally divergent, and 
its expression is restricted to regulatory T lymphocytes46. The critical residues of the KEPE SUMOylation motif 
in FOXP2 are conserved in FOXP1 and FOXP4, which is particularly striking because the C-terminal regions of 
these proteins generally exhibit a low level of similarity (the region is absent in FOXP3) (Fig. 7a,b). This low level 
(blue). (f) Gel shift assay for FOXP2 SUMOylation. HEK293 cells were transfected with FOXP2-UBC9 (wild-
type (WT), K674R or R553H mutant) together with mCherry-SUMO3 and myc-tagged PIAS1. Top panel: 
western blot probed with anti-V5. The 110 kDa species is unmodifed FOXP2-UBC9. The 170 kDa species is 
FOXP2-UBC9 modified with mCherry-SUMO3. Second panel: western blot probed with anti-myc tag antibody 
to detect PIAS1. Third panel: western blot probed with anti-mCherry. The asterisk indicates unconjugated 
mCherry-SUMO. Higher molecular weight species are cellular proteins modified with mCherry-SUMO. 
Bottom panel: western blot probed with anti-β -actin to confirm equal loading.
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of sequence conservation in the C-terminal region of the FOXP proteins is consistent with the polypeptide in this 
region being structurally disordered, in order to maintain accessibility of the SUMOylation site40.
The conservation of the SUMOylation site in FOXP1 prompted us to assess if this protein may also be subject 
to PIAS-mediated SUMOylation. The essential role of FOXP1 in brain development has recently come to light 
since it was discovered that haploinsufficiency of FOXP1 is associated with intellectual disability, autistic features, 
expressive speech deficits and dysmorphic features27,47–50. The FOXP1-related disorder is more severe than that 
resulting from haploinsufficiency of FOXP2, indicating that the two proteins have non-redundant functions in 
human brain development51. Furthermore, and in contrast to aetiological FOXP2 variants, all aetiological FOXP1 
variants reported to date have occurred de novo27,47. In a BRET assay, FOXP1 and FOXP2 exhibited similar 
levels of interaction with PIAS1, PIAS2 and PIAS4, but unlike FOXP2, FOXP1 showed little or no interaction 
with PIAS3 (Fig. 7c). BRET assays also showed clear interaction of FOXP1 with all three SUMOs (Fig. 7d). It is 
therefore likely that FOXP1 is also subject to modification by SUMO1, SUMO2 and SUMO3, at an equivalent 
site to that in FOXP2 (K636), but that the members of the PIAS family have differing levels of importance in the 
SUMOylation of FOXP1 and FOXP2. Three proteome-wide studies of SUMOylation in human cell lines have also 
identified FOXP1 and FOXP4 as substrates for SUMOylation, supporting a conserved role for SUMOylation in 
the regulation of FOXP transcription factors52–54.
Figure 7. The FOXP2 paralogue FOXP1 is also SUMOylated (a) Left: Schematic representation of the FOXP 
family of proteins. Known domains are shown in dark blue: glutamine-rich region (Q-rich); zinc finger (ZF); 
leucine zipper (LZ); forkhead domain (FOX). The number of amino acid residues is indicated to the right of 
the schematic. Right: identity matrix for FOXP proteins. (b) Sequence alignment of the region surrounding the 
SUMOylation site in FOXP proteins. Conserved residues are shown on a black background. Critical residues 
of the KEPE-type SUMOylation site motif are shown in turquoise and the SUMO conjugation site is labeled. 
UniProt accession numbers: FOXP2 O15409; FOXP1 Q9H334; FOXP4 Q8IVH2. (c) BRET assay for interaction 
of FOXP1 and FOXP2 with PIAS proteins. HEK293 cells were transfected with luciferase-FOXP1 or luciferase-
FOXP2 (donor) and YFP-PIAS (acceptor). The control donor protein is a nuclear-targeted luciferase. Values 
are mean corrected BRET ratios ± S.E.M. (n = 3). (d) BRET assay for interaction of FOXP1 and FOXP2 with 
SUMO. HEK293 cells were transfected with luciferase-FOXP1 or luciferase-FOXP2 (donor) and YFP-SUMO 
(wild-type (GG) or alanine mutant (AA), acceptor). The control donor protein is a nuclear-targeted luciferase. 
Values are mean corrected BRET ratios ± S.E.M. (n = 3).
www.nature.com/scientificreports/
13Scientific RepoRts | 6:20911 | DOI: 10.1038/srep20911
Discussion
In this study we have shown that FOXP2 has a single major SUMOylation site at K674, which can be modified 
by SUMO1, SUMO2 and SUMO3. This site is fully conserved in orthologues of FOXP2, and lies within the 
C-terminal region of the protein, which previously had no known function. We have demonstrated that FOXP2 
interacts with members of the PIAS family of E3 SUMO ligases, and that this interaction probably involves the 
SP-RING domain of PIAS and the N-terminal region of FOXP2. The interaction between FOXP2 and PIAS pro-
teins causes relocalization of FOXP2 to nuclear speckles, and promotes SUMOylation of FOXP2. The FOXP2 
paralogues FOXP1 and FOXP4 probably also undergo PIAS-mediated SUMOylation at equivalent sites.
SUMOylation is believed to occur in all cell types and across all developmental stages, and thousands 
of nuclear proteins are thought to be modified in this way31. The essential role of SUMOylation in develop-
ment is evidenced by the early embryonic lethality resulting from Ubc9 knockout in mice55. Global changes 
in SUMOylation levels during brain development have been documented in mouse and rat, but the functional 
impact of these changes is uncertain56,57. Effects of SUMOylation on several neural proteins have been reported, 
with impacts on neuronal specification and dendritic and synaptic morphogenesis, but for most proteins the 
function of SUMOylation remains unclear31,58.
In our cellular assays, abolishing the major SUMOylation site in FOXP2 did not produce changes in subcellu-
lar localization, stability, transcriptional regulation, dimerization with wild-type FOXP2, or interaction with the 
co-repressor CtBP1. Abolition of the SUMOylation site may have effects on unknown protein interactions, or on 
regulation of a particular subset of target genes. It would therefore be of interest in future to perform proteomic 
and transcriptomic studies to search for protein-protein interactions and target genes that are affected by loss 
of the FOXP2 SUMOylation site. At the same time, the failure to observe differences between wild-type FOXP2 
and the K647R mutant is not necessarily surprising given the small proportion of wild-type protein molecules 
modified by SUMOylation at any one time. Like several other post-translational modifications, SUMOylation is 
a dynamic, reversible process which allows protein activity to be regulated on short time-scales in response to 
external signals that may change over the course of development. The consequences of loss of SUMOylation in 
FOXP2 may therefore only be apparent in the context of a developing organism, and SUMOylation of FOXP2 
is potentially essential in vivo but not in cultured cells. It would therefore be interesting to abolish the FOXP2 
SUMOylation site in an animal model, in order to assess the effect of loss of SUMOylation on developmental 
regulation of gene expression. There are still very few examples of animal models in which a SUMOylation site 
in a specific protein has been ablated. However, abolishing the SUMOylation sites of the transcription factor 
NR5A1 in the mouse resulted in aberrant regulation of target genes and prominent endocrine abnormalities, 
without affecting protein stability or localization59, consistent with the suggestion that the consequences of loss 
of SUMOylation may only be apparent in an organismal context. To our knowledge there has been no systematic 
survey of rare variants in human developmental disorders for changes likely to affect SUMOylation. Thus, the 
importance of SUMOylation of specific proteins to normal development is not yet fully appreciated.
The rapid and dynamic nature of SUMOylation makes it well suited as a mechanism for modifying the activity 
of proteins such as FOXP2 in response to activity within neural circuits. Such mechanisms may be important for 
supporting neural plasticity, a process in which FOXP2 orthologues have been shown to play a role in animal 
models9,14,21. The absolute conservation of the SUMOylation site and surrounding KEPE motif in FOXP2 ortho-
logues and in the paralogues FOXP1 and FOXP4 suggests that SUMOylation may be an evolutionarily ancient 
and conserved mechanism for regulating the activity of these transcription factors in the brain and elsewhere, 
both during development and in the adult organism.
The selection of target proteins for SUMOylation is mediated by SUMO E3 ligases, such as members of the 
PIAS family. Our results indicate that multiple PIAS proteins may participate in FOXP SUMOylation in vivo, 
and that different PIASs may be involved in the SUMOylation of different FOXPs. RNA expression data from the 
Human Protein Atlas (www.proteinatlas.org) suggests that the four PIAS proteins have ubiquitous expression, 
with PIAS1 and PIAS3 showing moderate expression levels across all tissues tested, whereas PIAS2 and PIAS4 
have lower average expression levels with high expression in testis. However the PIAS proteins are not function-
ally redundant, because Pias1 knockout mice exhibit perinatal lethality, whereas Pias2 and Pias4 knockouts have 
no obvious phenotype (Pias3 knockouts have not yet been reported)60–62. There may be some temporal or spatial 
specificity in the interaction of PIASs with FOXPs, and we also do not exclude the involvement of other kinds of 
SUMO E3 ligase in the SUMOylation of FOXPs.
The reduced level of SUMOylation of the R553H mutant, and the reduced interaction of the mutant with 
PIAS proteins, indicate that mutations within the FOX domain of FOXP2 can interfere with PIAS-mediated 
SUMOylation. Interestingly, PIAS1-mediated SUMOylation has also been reported for FOXL2 and FOXA2, 
which belong to different subfamilies of the FOX transcription factor family63,64. The different subfamilies of 
FOX proteins show little similarity outside the FOX domain, raising the possibility that the FOX domain may 
act in concert with other subfamily-specific protein regions to promote SUMOylation of FOX transcription fac-
tors. Aetiological mutations have been reported in the FOX domains of several other FOX transcription fac-
tors65, but the effects of these mutations on protein SUMOylation have not been investigated. We predict that 
disorder-related FOX domain mutations would disrupt SUMOylation of other FOX transcription factors, includ-
ing FOXP1.
Concurrently with the submission of this manuscript, SUMOylation of FOXP2 by SUMO1 and SUMO3 
was reported by an independent research group66. In agreement with our findings, this report identified K674 
as the major SUMOylation site in FOXP2, and found that the R553H variant displays reduced SUMOylation. 
Furthermore, no effect on protein stability or localization was observed when mutating the SUMOylation site, 
in line with our data. Some potential small effects on transcriptional regulation in luciferase reporter assays 
were observed, including for SRPX2, using a similar reporter construct to that employed in our experiments, 
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emphasizing that the effects of SUMOylation on FOXP2-mediated transcriptional regulation warrant fur-
ther investigation, ideally in a more biologically-relevant model, and that the effects of SUMOylation may be 
promoter-dependent.
SUMOylation is currently the only confirmed post-translational modification of FOXP2. A key part of the 
way SUMOylation affects protein function is through interaction with other post-translational modifications, for 
example by competition with ubiquitination and acetylation for modification of specific lysine side chains. Our 
findings thus emphasize the need to investigate further the post-translational modifications of FOXP2 in order 
to understand how the activity of this transcription factor may be dynamically regulated in the developing and 
adult brain.
Methods
Yeast two-hybrid assay. The yeast two-hybrid assay was performed by Dualsystems Biotech AG 
(Switzerland). The bait construct was produced by fusing the coding sequence of full-length human FOXP2 
(Uniprot accession O15409) to the DNA-binding domain of the bacterial transcription factor LexA. Preys con-
sisted of a human foetal brain cDNA library fused to the activation domain of yeast Gal4. LacZ was used as the 
reporter gene and interactions identified by the presence of blue colour. It was confirmed that transfection of 
the FOXP2 bait construct alone did not activate transcription of the reporter gene. False positive interactors 
were removed using the bait dependency test to identify prey constructs which activated transcription without 
co-transfection with the FOXP2 bait construct.
DNA constructs. The coding sequences of PIAS1 (NM_016166.1), PIAS2 (NM_004671.3), PIAS3 
(NM_006099.3), PIAS4 (NM_015897.1), SUMO1 (NM_003352.4), SUMO2 (NM_006937.3), and SUMO3 
(NM_001286416.1), and a 1146 bp region of the promoter of SRPX2, were amplified from human foetal brain 
cDNA using the primers listed in Supplementary Table S4. The cloning of wild-type FOXP2, FOXP1 and CtBP1, 
and of synthetic truncated forms of FOXP2, has been described previously27–29. For expression of fusion pro-
teins with Renilla luciferase, YFP and mCherry, cDNAs were subcloned into the pLuc, pYFP and pmCherry 
expression vectors, respectively, which have been described previously28,29. For expression of proteins with three 
tandem N-terminal Myc tags or an N-terminal V5 tag, cDNAs were subcloned into vectors which were created 
by modification of the vector pEGFP-C2 (Clontech), and have an identical backbone to the pLuc, pYFP and 
pmCherry vectors, with the exception of the N-terminal tag and polylinker. To generate the FOXP2-UBC9 fusion 
protein, the UBC9 coding sequence (NM_194260.2) plus 58 upstream nucleotides were fused to the 3′ end of the 
FOXP2 coding sequence in the V5-tag vector, removing the FOXP2 stop codon. The FOXP2 K674R and R553H 
mutants, PIAS1 C350S mutant, and SUMO alanine mutants were generated by site-directed mutagenesis using 
the Quick-Change Site-Directed Mutagenesis kit (Stratagene) following the manufacturer’s protocol. Primers 
used in site-directed mutagenesis are listed in Supplementary Table S5. The SRPX2 luciferase reporter plasmid 
was generated by subcloning a 1146 bp region of the SRPX2 promoter into the promoterless firefly luciferase 
vector pGL4.23 (Promega). All constructs were verified by Sanger sequencing. Plasmid sequences are available 
upon request.
Cell culture and transfection. HEK293 were obtained from ECACC (cat. no. 85120602) and cultured in 
DMEM supplemented with 10% foetal bovine serum. HeLa-SUMO3 cells, which stably express SUMO3 with 
an N-terminal hexahistidine tag42, and the parental HeLa cell line, were kindly provided by Professor Ronald 
Hay and Dr Michael Tatham, and were cultured in DMEM supplemented with 10% foetal bovine serum (with 
the addition of 5 μ M puromycin for the HeLa-SUMO3 cell line). Transfections were performed using GeneJuice 
(Merck-Millipore) according to the manufacturer’s instructions.
BRET assay. BRET assays were performed as described29.
Fluorescence microscopy. HEK293 cells were seeded on coverslips coated with poly-L-lysine. Cells were 
cultured for 30 h post-transfection, and then fixed with methanol and nuclei were stained with Hoechst 33342. 
Fluorescence images were acquired using a Zeiss LSM510 confocal microscope with LSM Image Software or a 
Zeiss Axio Imager 2 upright fluorescence microscope with ApoTome.2 using ZEN Image software.
Gel shift assay. HEK293 cells were transfected in 6-well plates and cultured for 48 h. Cells were lysed in 
300 μ L of Laemmli sample buffer containing 10% Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) and 
incubated for 10 min at 95 °C. Proteins were resolved on 10% SDS-polyacrylamide gels and transferred to PVDF 
membranes using a TransBlot Turbo Blotting apparatus (Bio-Rad). Membranes were blocked in PBS containing 
5% milk and 0.1% Tween-20 and incubated overnight at 4 °C with primary antibody. The following antibod-
ies were used: anti-GFP (Clontech cat. no. 632380, 1:8000, for YFP constructs); anti-mCherry (Novus cat. no. 
NBP1-96751, 1:1000); anti-V5 tag (Genetex cat. no. GTX42525, 1:3000); anti-Myc tag (Abcam cat. no. ab9106, 
1:1000); anti-β -actin (Sigma cat. no. A5441, 1:10,000). After washing, membranes were incubated with horse-
radish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG for 45 min at room temperature. Proteins were 
visualized using Novex ECL Chemiluminescent Substrate Reagent Kit (Life Technologies) and a ChemiDoc 
XRS + imaging system (Bio-Rad). Densitometry was performed using the Chemidoc XRS + System image anal-
ysis software (Bio-Rad).
Pull-down assay. Purification of SUMO3 conjugates from HeLa cells stably expressing His-tagged 
SUMO3 was performed as previously described42. Briefly, cells were seeded in 6-well plates and transfected with 
YFP-tagged FOXP2 variants or YFP alone. After 48 h cells were lysed in 6 M Guanidinium-HCl, 10 mM Tris, 
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100 mM Sodium phosphate buffer pH 8.0, 5 mM β -mercaptoethanol and 5 mM imidazole. An aliquot of the 
lysate (10%) was retained as the input sample and the remainder was incubated with His-tag Dynabeads (Life 
Technologies) overnight at 4 °C with rotation. Beads were washed with 8 M Urea, 10 mM Tris pH 6.3, 100 mM 
sodium phosphate buffer, 0.1% Triton x-1000 and 5 mM β -mercaptoethanol. SUMO3 conjugates were eluted 
by incubation at room temperature for 20 min in 200 mM imidazole, 150 mM Tris pH 8.0, 5% SDS, 30% glyc-
erol, 720 mM β -mercaptoethanol and 0.0025% bromophenol blue. Western blotting was performed as described 
above; His-tagged SUMO3 conjugates were detected using an anti-His tag antibody (Abgent cat. no. AM1010a, 
1:1000).
Protein degradation assay. HEK293 cells were transfected in 6-well plates and cultured for 48 h. 
Cycloheximide was added for the indicated times at a final concentration of 50 μ g/ml. Cells were lysed for 10 min 
at 4 °C with 100 mM Tris pH 7.5, 150 mM NaCl, 10 mM EDTA, 0.2% Triton X-100, 1% PMSF, and protease inhib-
itor cocktail. Cell lysates were cleared by centrifugation at 10,000×g for 3 min at 4 °C. Gel electrophoresis, western 
blotting and densitometry were performed as described above.
Fluorescence-based measurement of protein expression levels. HEK293 cells were transfected 
with YFP-FOXP2 and mCherry in clear-bottomed black 96-well plates in triplicate. Cells were cultured in a 
TECAN M200PRO microplate reader at 37 °C with 5% CO2. Fluorescence intensity measurements were taken at 
multiple time points. For each well and time point, the background-subtracted YFP intensity was divided by the 
background-subtracted mCherry intensity. Triplicate conditions were averaged.
Luciferase assays. HEK293 cells were seeded in clear-bottomed white 96-well plates and transfected in 
triplicate. For the SV40 assay, cells were transfected with 12 ng of pGL3-promoter firefly luciferase reporter con-
struct (Promega), 5 ng of pRL-TK Renilla luciferase normalization control (Promega), and 16 ng of YFP-FOXP2 
(wild-type or K674R or R553H mutant) or YFP control construct. For the SRPX2 assay, cells were transfected 
with 4.3 ng of SRPX2 luciferase reporter construct, 5 ng of pGL4.74 Renilla luciferase normalization control 
(Promega), and 45 ng of YFP-FOXP2 (wild-type or K674R or R553H mutant) or YFP control construct. After 
48 h, luciferase activity was measured in a TECAN F200PRO microplate reader using the Dual-Luciferase 
Reporter Assay system (Promega).
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